The majority of experimental atherosclerosis studies evaluating the impact of SGLT2 inhibitors have been performed in apolipoprotein E deficient mice with and without diabetes mellitus [63,64,65,66,67]. Here, SLC5A2 is linked to diabetes mellitus.